Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Commissioner Nominee Not ‘Pro-Industry Choice,’ GLP-1 Compounding Could Be First Clash

Nov 26 2024

• By Sarah Karlin-Smith

Marty Makary — Martin Makary testifies at a Senate roundtable in September. (Screenshot)

Related Content

Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning

Aug 16 2022

Drug Compounding Can't Be Justified By Price, FDA Says

Jul 10 2016

GLP-1s: Compounders Get Temporary Reprieve But US FDA May Be Building Stronger Case

Oct 14 2024

Potential FDA Positions In The Political Crosshairs

Nov 25 2024

Califf Confirmation Hearing Round Two: Industry Ties Once Again May Bark Loud, Bite Lightly

Nov 12 2021

Gottlieb's Confirmation: Will Industry Ties Remain A Big Deal After The Hearing?

Apr 03 2017

Related Companies

Novo Nordisk A/S

Eli Lilly and Company

Harrow, Inc.

More from US FDA

More from Legislation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window